A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
PPI-668 is an antiviral agent (a hepatitis C NS5A inhibitor) that is being developed as a
potential treatment for hepatitis C virus infection. This study is being done to assess the
safety and tolerance of PPI-668 when given to healthy volunteers for up to 5 days (Part I of
the study) and to hepatitis C patients for up to 3 days (Part II). In addition, the study
will assess how much PPI-668 is absorbed into the bloodstream. In Part II, the effect of
PPI-668 on the amount of hepatitis C virus in patients' bloodstream (serum HCV RNA levels)
also will be assessed.